BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

...from Mass Eye and Ear Last week, Biogen Inc. (NASDAQ:BIIB) gained exclusive, worldwide rights from Massachusetts Eye and Ear...
...processing factor 31 BC Staff Dragonfly Therapeutics Inc. Bristol Myers Squibb Co. HiberCell Inc. Biothera Pharmaceuticals Inc. Case Western Reserve University Biogen Inc. Massachusetts Eye and Ear LMY-920 Luminary...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...meek B cell vaccines,” said Luk Vandenberghe, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear...
...Capacity for COVID-19 Vaccines” ). Targets SARS-CoV-2 S - SARS-CoV-2 spike protein Karen Tkach Tuzman, Associate Editor Massachusetts Eye and Ear Massachusetts...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...of manufacturers in COVID-19 countermeasures. The AAVCOVID vaccine program, spearheaded by Massachusetts General Hospital and Massachusetts Eye and Ear...
BioCentury | Apr 1, 2020
Emerging Company Profile

Affinia: Optimizing for AAV vector function

...see “Mapping the Path to Gene Therapy 2.0” ). Vandenberghe is an associate professor at Massachusetts Eye and Ear...
...Waltham, Mass. Technology: Rational AAV vector design platform Origin of technology: Lonza Group Inc. and Massachusetts Eye and Ear...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...of Editas Medicine Inc. (NASDAQ:EDIT) and serves on the boards of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Massachusetts Eye and Ear...
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...retinal diseases. The first program will deliver RPGRIP1 via Anc80, a vector system developed by Massachusetts Eye and Ear...
BioCentury | Sep 14, 2018
Product R&D

Academia’s manufacturing problem

...The Boston-based non-profit was founded in 2016 by biotech entrepreneur Scott Dorfman and two non-profits: Massachusetts Eye and Ear...
...for discount vector manufacturing and reserved manufacturing slots. Both Lonza and Odylia have rights from Massachusetts Eye and Ear...
...Molecular Therapeutics Inc., Emeryville, Calif. Indiana University, Indianapolis, Ind. Lonza Group Ltd. (SIX:LONN), Basel, Switzerland Massachusetts Eye and Ear...
BioCentury | Aug 10, 2018
Finance

Sound story

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
BioCentury | Aug 10, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...in Akouos' $7.5 million seed round in December (see "Akouos Licenses Gene Therapy Tech From Massachusetts Eye and Ear"...
...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...Smith, former CEO of Cochlear Ltd. (ASX:COH). Akouos Inc., Boston, Mass. Elizabeth S. Eaton Akouos Inc. Harvard Medical School Massachusetts Eye and Ear...
BioCentury | Aug 7, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...candidate in 2020. In a pair of papers published last year in Nature Biotechnology , Massachusetts Eye and Ear...
Items per page:
1 - 10 of 54
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

...from Mass Eye and Ear Last week, Biogen Inc. (NASDAQ:BIIB) gained exclusive, worldwide rights from Massachusetts Eye and Ear...
...processing factor 31 BC Staff Dragonfly Therapeutics Inc. Bristol Myers Squibb Co. HiberCell Inc. Biothera Pharmaceuticals Inc. Case Western Reserve University Biogen Inc. Massachusetts Eye and Ear LMY-920 Luminary...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...meek B cell vaccines,” said Luk Vandenberghe, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear...
...Capacity for COVID-19 Vaccines” ). Targets SARS-CoV-2 S - SARS-CoV-2 spike protein Karen Tkach Tuzman, Associate Editor Massachusetts Eye and Ear Massachusetts...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...of manufacturers in COVID-19 countermeasures. The AAVCOVID vaccine program, spearheaded by Massachusetts General Hospital and Massachusetts Eye and Ear...
BioCentury | Apr 1, 2020
Emerging Company Profile

Affinia: Optimizing for AAV vector function

...see “Mapping the Path to Gene Therapy 2.0” ). Vandenberghe is an associate professor at Massachusetts Eye and Ear...
...Waltham, Mass. Technology: Rational AAV vector design platform Origin of technology: Lonza Group Inc. and Massachusetts Eye and Ear...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...of Editas Medicine Inc. (NASDAQ:EDIT) and serves on the boards of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Massachusetts Eye and Ear...
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...retinal diseases. The first program will deliver RPGRIP1 via Anc80, a vector system developed by Massachusetts Eye and Ear...
BioCentury | Sep 14, 2018
Product R&D

Academia’s manufacturing problem

...The Boston-based non-profit was founded in 2016 by biotech entrepreneur Scott Dorfman and two non-profits: Massachusetts Eye and Ear...
...for discount vector manufacturing and reserved manufacturing slots. Both Lonza and Odylia have rights from Massachusetts Eye and Ear...
...Molecular Therapeutics Inc., Emeryville, Calif. Indiana University, Indianapolis, Ind. Lonza Group Ltd. (SIX:LONN), Basel, Switzerland Massachusetts Eye and Ear...
BioCentury | Aug 10, 2018
Finance

Sound story

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
BioCentury | Aug 10, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...in Akouos' $7.5 million seed round in December (see "Akouos Licenses Gene Therapy Tech From Massachusetts Eye and Ear"...
...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...Smith, former CEO of Cochlear Ltd. (ASX:COH). Akouos Inc., Boston, Mass. Elizabeth S. Eaton Akouos Inc. Harvard Medical School Massachusetts Eye and Ear...
BioCentury | Aug 7, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...candidate in 2020. In a pair of papers published last year in Nature Biotechnology , Massachusetts Eye and Ear...
Items per page:
1 - 10 of 54